This compound is supplied for in-vitro and preclinical research only. It is not a medicinal product. It is not approved for human or veterinary use in any jurisdiction. No therapeutic, medicinal, cosmetic, or performance-enhancement claims are made or implied. By proceeding to inquire, you confirm you are an adult researcher acquiring this compound within your own research framework. Full terms on the Research Use Only page.
DSIP
5 mg freeze-dried vial, nonapeptide neuropeptide
Compound specifications, chemistry, and storage.
Technical specifications
Specimen format| Compound name | DSIP (Delta Sleep-Inducing Peptide) |
| Also known as | Delta sleep-inducing peptide, DSIP, sleep peptide |
| CAS number | 62568-57-4 |
| PubChem CID | 68815 → |
| InChI Key | Reference InChI Key on COA |
| SMILES | Reference SMILES on COA |
| Empirical formula (Hill notation) | C35H48N10O15 |
| Molecular weight | 848.81 g/mol (monoisotopic mass: 848.33) |
| Salt form | Acetate (default) |
| Counter-ion content | Quantified per batch on COA. Custom salt forms (chloride, ammonium, TFA) available on quote. |
| Sequence (1-letter) | WAGGDASGE |
| Sequence (3-letter) | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Length | 9 amino acids (nonapeptide) |
| Weight basis | Gross weight per industry standard. Net peptide content quantified on batch COA. |
| Quantity per vial | 5 mg |
| Format | Freeze-dried white powder or thin film, sealed under inert atmosphere. Why does the vial look empty? |
| Appearance | White freeze-dried cake or powder. May also appear as a thin film on the vial wall. |
| Solubility | Water soluble, reconstituted with bacteriostatic water (1 to 2 ml typical) |
| Solution colour | Clear and colourless when correctly reconstituted |
| Purity (HPLC) | Specification ≥98.5%, tested before listing |
| Identity confirmation | LC-MS, batch-specific spectrum on COA |
| Endotoxin (LAL) | Within Ph. Eur. specification, batch report on COA |
| Storage (freeze-dried) | 2 to 8 degrees Celsius, sealed, protected from light. Avoid thermal cycling. |
| Storage (reconstituted) | 2 to 8 degrees Celsius. Use within 4 to 6 weeks. Avoid repeated freeze-thaw. |
| Shelf life | 24 months from synthesis date when storage conditions are maintained |
| Country of synthesis | EU partner facility, Ph. Eur. methodology references |
| Application | In-vitro and preclinical research only. Not for human or veterinary use. |
A sleep-related nonapeptide, and what the published research says about it.
DSIP is a synthetic nine-amino-acid peptide first isolated from rabbit cerebral venous blood in 1977 by the Schoenenberger-Monnier group, named for its observed correlation with delta-wave electroencephalographic activity in animal sleep studies. The endogenous origin and physiological role of the peptide remain partially characterised in the published literature. Published research investigates the peptide in animal sleep models, stress-response pathways, and neuroendocrine modulation. The sections below summarise what the published research investigates, what Cresten supplies, and what the certificate of analysis confirms.
Where DSIP comes from.
DSIP (delta sleep-inducing peptide) is a synthetic nine-amino-acid peptide first isolated in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation that produced delta-wave electroencephalographic activity. The isolation work was conducted by the research group of Marcel Monnier and Guido Schoenenberger at the University of Basel, and the peptide was named for its observed correlation with the delta-wave sleep state in donor animals. The endogenous biological source and the precise physiological role of the peptide in mammals remain partially characterised in the published literature five decades after the original isolation.
The peptide is built by Fmoc solid-phase peptide synthesis. The sequence is short (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and contains no unusual residues or modifications. After purification by reversed-phase HPLC the peptide is freeze-dried and sealed in vials. The plasma half-life is short (roughly 7 to 15 minutes), reflecting rapid clearance through unknown enzymatic pathways.
PubMed lists roughly 300 papers mentioning DSIP or delta sleep-inducing peptide as of 2026. The published research is concentrated in animal sleep models, stress-response pathways, neuroendocrine modulation, and a separate strand of research examining the peptide in pain-modulation contexts. Accredited replication of the original observation that the peptide induces delta-wave sleep has produced mixed results in the published literature, and the modern interpretation of the original 1977 observation remains an active area of discussion.
What the research looks at.
DSIP mechanism research has not converged on a defined receptor or molecular target in the published literature. Cell-culture binding studies have not identified a high-affinity receptor-binding partner for the peptide that is consistent across the published research. The mechanistic pathways through which the peptide produces measurable effects in animal models remain incompletely characterised, distinguishing DSIP from peptides such as the GHRPs and GLP-1 analogues for which receptor pharmacology is well-defined.
A second strand of research has examined neuroendocrine effects in animal models. Published studies measure the effects of peptide administration on hypothalamic-pituitary-adrenal axis activity, with reports of altered corticotropin and corticosteroid responses to stress challenges in animals administered DSIP versus vehicle controls. The published interpretation is that the peptide modulates stress-response pathways through unknown molecular routes; the literature is consistent in describing modulation rather than direct activation or inhibition of defined pathways.
"Five decades after its original isolation, DSIP does not have a well-defined receptor or molecular target in the published research."
A third line of research has examined the peptide in pain-modulation contexts. Animal studies in defined pain-model designs have measured pain-threshold endpoints and inflammatory-marker measurements in animals administered the peptide. The published findings describe modulatory effects rather than direct analgesic activity, with the mechanistic basis for the effects unclear in the literature. Replication across research groups has been mixed.
Where the published research does not go: there are no FDA or EMA approvals for DSIP in any indication. The original observation that the peptide induces delta-wave sleep has not been replicated reliably across accredited research groups. The compound is supplied as a research compound for laboratory research only.
What the certificate confirms.
Every Cresten batch of BPC-157 ships with a certificate from an analytical lab, against the test panel described on the Methodology page. The certificate that ships with your batch confirms:
The certificate format is shown on the batch verification page.
Selected published research on DSIP.
Monograph last reviewed 26 May 2026 · references checked against PubMed
The curated reference list for DSIP is being finalised against PubMed and will appear here. In the meantime, the indexed literature is available directly: PubMed results for DSIP.
What this monograph is not
This monograph summarises what the published research looks at regarding BPC-157 mechanism. It is not a therapeutic recommendation. It is not dosing guidance. It is not a clinical protocol. It is not medical advice.
Cresten Labs supplies BPC-157 as a research compound for lab-based research only. The decision to investigate any compound in any research framework is the researcher’s decision, within their own ethical, legal, and methodological boundaries.
Cresten makes no claim about human therapeutic use, no claim about clinical effectiveness, no claim about safety in human use, and no claim that this compound has been reviewed by any regulator for any medical use.
Frequently asked questions about DSIP
Common research-protocol and supply questions about DSIP, with answers grounded in published peer-reviewed research and Cresten Labs supply practice. All information is for in vitro and preclinical research only.
What is DSIP?
DSIP is delta-sleep-inducing peptide, a 9-amino-acid peptide (CAS 62568-57-4, molecular weight 848.81 g/mol). Cresten Labs supplies DSIP as a freeze-dried vial for in vitro and preclinical research only, with each batch verified at Janoshik Analytical.
What does research suggest DSIP does?
Published research investigates DSIP for modulating delta-wave sleep architecture in research models. The compound is studied primarily in sleep architecture and circadian research. DSIP is supplied for research use only and is not approved by any regulator for medical use.
What is the typical DSIP dosage in published research?
Published DSIP dosage in research protocols ranges from 100 to 500 mcg per administration, administered subcutaneously, with evening dosing before sleep in sleep-architecture research. Cresten Labs publishes the typical DSIP protocol ranges as research-protocol references only; this is not dosing guidance for human use.
How do I reconstitute DSIP for research?
Standard DSIP reconstitution adds 2 mL plain bacteriostatic water for the 5 mg vial. Cresten ships lyophilized DSIP vials for reconstitution by the researcher per their protocol.
What is the DSIP half-life and how is DSIP storage handled?
Published research reports DSIP systemic half-life at short systemic half-life. DSIP storage: lyophilized vial stable at room temperature for shipping; reconstituted solution stored at 2 to 8 °C and used within 28 days. The Cresten certificate of analysis lists the synthesis date, batch identifier, and the storage conditions verified for this specific batch.
What does the research literature report about DSIP side effects?
Published DSIP research reports the following: preclinical research reports tolerability across tested dose ranges. Cresten Labs supplies the compound for research use only; clinical-use side-effect data should be drawn from peer-reviewed clinical trial publications, not from research-vendor pages.
What is the typical DSIP protocol duration in research?
Published DSIP protocol research typically runs evening dosing before sleep in sleep-architecture research. The DSIP protocol duration depends on the research question being studied. The Cresten reconstitution calculator includes a schedule planner that flags the 28-day refrigerated shelf-life of the reconstituted solution.
Where to buy DSIP in Europe?
Cresten Labs supplies DSIP across the EU single market to 16 European countries. Each DSIP batch is tested at Janoshik Analytical with the certificate of analysis published on the website before it lists. DSIP is sold for in vitro and preclinical research only, not for human or veterinary use.
How is DSIP verified at Cresten Labs?
Every DSIP batch is tested at Janoshik Analytical in Czech Republic, an third-party peptide-analysis laboratory. Each batch certificate documents HPLC purity, mass-spectrometry identity confirmation, and contamination panels. The certificate publishes with the batch, before it lists.
Is DSIP legal to import for research in the EU?
Research-use peptides supplied with proper documentation are legally importable into EU member states for in vitro and preclinical research. Cresten ships DSIP from inside the EU single market, so no customs declaration is required for shipments within EU member states. Local research-use regulations apply.